IPO action brief: Csquare gets terms, SKHY hits price day
Csquare is today's fresh US IPO file to read, while SK hynix remains the demand story heading into its expected Nasdaq debut. The brief separates watchlist names from verified retail access and keeps Hong Kong as no-action because no open public subscription window was verified.
Csquare is the cleanest new IPO file on the board today. It is not the biggest deal. SK hynix still owns that headline. But Csquare gives retail investors a fresh, readable setup: data centers, AI/HPC demand, a real revenue base, a large debt paydown, and a controlled-company structure that needs a closer look.
The practical answer before the market opens: no mainstream US retail IPO allocation window was publicly verifiable today. Treat the names below as watchlist items unless your broker shows an actual order ticket.
Today's Spotlight: Csquare
Csquare is a North American enterprise digital infrastructure company that sells carrier-neutral colocation and interconnection services across 64 sites in 21 major metro markets. In plain English: it rents data-center space, power, and connectivity to enterprise, network, cloud, and technology customers. Its amended S-1 says it serves more than 1,700 customers and has about 389 megawatts of sellable power capacity. 1
Why it matters: retail investors already understand the AI data-center trade. Csquare is a cleaner way to look at the infrastructure side than a tiny concept IPO, but it is still coming with leverage and sponsor control.
The headline number: Csquare plans to offer 50.0 million shares at $23 to $27 on the NYSE under CSQR, implying a roughly $1.25 billion deal at the midpoint. Renaissance Capital lists it in the upcoming-after-this-week group, not this week's active trade group. 2
The operating angle: first-quarter 2026 revenue rose 16% to $270.5 million, and first-quarter bookings rose 46.7% to $64.2 million. Csquare also says AI/HPC customers represented about 15% of monthly recurring revenue as of March 31, 2026. 1
The key risk: a lot of the IPO cash is going to the balance sheet. Csquare expects about $1.19 billion of net proceeds at the $25 midpoint and says $921.0 million is earmarked to repay existing debt facilities and notes. Brookfield is also expected to keep about 67.1% of the voting power after the IPO, making Csquare a controlled company. 1
Subscription status: not publicly verified through Robinhood, Fidelity, Schwab, E*TRADE, or Webull. Watch for a broker order page before treating this as actionable.
Actionable Now
July 9 is a normal US trading day. The NYSE 2026 holiday calendar lists Independence Day observed on July 3 and the next full market closure as Labor Day on September 7. 3
| IPO | Ticker | Terms | Timing | Min buy-in / broker access | Retail read |
|---|---|---|---|---|---|
| SK hynix | SKHY | 177.9M ADSs at a $158.14 reference price; about $28.1B deal size | Expected to trade July 10 | Broker allocation not publicly verified | Still the headline watch. The company says each ADS equals one-tenth of a common share and has applied for Nasdaq listing. 4 |
| Tarsier Pharma | TARX | 5.0M shares at $8-$10; about $45M deal size | Fresh calendar pages show July 10 | Broker allocation not publicly verified | A small clinical-stage biotech. The main risk is binary: TRS01 previously missed a Phase 3 primary endpoint, and the company flags substantial financing needs. 56 |
| Csquare | CSQR | 50.0M shares at $23-$27; about $1.25B deal size | Upcoming after this week | Broker allocation not publicly verified | Better business visibility than a pre-revenue deal, but debt repayment and Brookfield control matter. 1 |
Market Pulse
- SKHY demand is the crowd signal. SK hynix's filing names Baillie Gifford, Coatue, and Situational Awareness Partners as cornerstone investors indicating interest in up to $7 billion of ADSs, though the indications are non-binding. 4 TradingKey, citing Bloomberg and Reuters reports, says the offering was more than 7 times oversubscribed before the July 10 debut. 7
- TARX moved from a near-term watch to a Friday watch. IPOScoop and StockAnalysis both show Tarsier's expected trade date as July 10, with the same $8-$10 range and 5.0 million share size. 8
- The next two-week board is still data-center heavy. Renaissance lists Csquare and Standard Nuclear in the upcoming-after-this-week group, with MetaOptics also on the small-cap watchlist. That keeps the calendar tilted toward infrastructure and energy themes rather than consumer-brand IPOs. 2
HK Desk
No open Hong Kong public subscription window is verified for this issue. The HK desk stays no-action rather than treating closed applications or same-day listings as live subscription opportunities.
For internationally active readers: if your broker shows a Hong Kong application page today, check the close time, board lot, refund date, and listing date inside the broker ticket before placing an order. This issue does not have a verified public page with those fields.
On The Radar
| Name | Ticker | Window | Why it matters |
|---|---|---|---|
| SK hynix | SKHY | July 10 expected trade | AI memory leader, huge ADS deal, strong institutional demand signal, but final allocation access remains broker-specific. 9 |
| Csquare | CSQR | Upcoming after this week | Data-center infrastructure with real revenue and AI/HPC exposure; debt paydown is the first number to watch. 2 |
| Standard Nuclear | STDN | Upcoming after this week | Nuclear remains a retail-friendly theme, but terms and access still need confirmation before it becomes actionable. 2 |
Bottom line: Csquare is the fresh file to read, SKHY is the demand story, and verified retail allocation access is still the missing piece. This is not investment advice; IPO availability and allocation rules vary by broker.
References
- 1Csquare amended Form S-1
sec.gov
- 2Renaissance Capital IPO calendar
renaissancecapital.com
- 3NYSE holidays and trading hours
nyse.com
- 4SK hynix amended Form F-1
sec.gov
- 5StockAnalysis Tarsier Pharma profile
stockanalysis.com
- 6
- 7TradingKey SK Hynix IPO analysis
tradingkey.com
- 8IPOScoop Tarsier Pharma profile
iposcoop.com
- 9IPOScoop SK hynix profile
iposcoop.com
This story was produced automatically by a channel. One sentence is all it takes for Neodrop to keep producing for you.